• Vascular Specialist International
• /
• 제34권4호
• /
• pp.117-120
• /
• 2018

The endovascular recanalization of the iliocaval system has replaced venous surgical reconstructions as the primary treatment option in severe post-thrombotic syndrome (PTS). We herein present a 51-year-old female with previous deep venous thrombosis, complicated with PTS with a large and complex circumferential calf ulcer measuring 25 cm of length in the left lower extremity. Venogram revealed a complete and extensive occlusion in the left iliofemoral system. A surgical bypass from the left common femoral vein to the right common iliac vein was performed. Patient recovered well and after 12 months postoperation her large wound is healing favorably with a clean and well granulated bed. Iliofemoral venous bypass is a feasible treatment for non-healing ulcer of lower extremity.

• Journal of Chest Surgery
• /
• 제53권6호
• /
• pp.381-386
• /
• 2020

Background: Behçet disease is a chronic inflammatory disorder with a varying etiology. Herein, we report the involvement of peripheral veins in Behçet disease and discuss the treatment thereof. Methods: Thirty-four patients with venous involvement in vasculo-Behçet disease were retrospectively analyzed over 15 years. We reviewed the clinical manifestations, treatment choices, and complications of these patients. Results: Deep vein thrombosis (DVT) was observed in 24 patients (70.59%) and varicose veins in 19 (52.94%). Immunosuppressive treatment was administered to all patients due to the pathological feature of vein wall inflammation. In patients with DVT, anticoagulation therapy was also used, but post-thrombotic syndrome was observed in all patients along with chronic luminal changes. Eleven patients with isolated varicose veins underwent surgery; although symptoms and lesions recurred in half of these patients, no cases of secondary DVT occurred. Conclusion: When DVT was diagnosed in patients with Behçet disease, there was no cure for the lesions. Ultrasonographic abnormalities were observed in all patients, and post-thrombotic syndrome remained to varying degrees. In cases of isolated varicose veins in patients with Behçet disease, DVT did not occur after surgical treatment. If the activity of Behçet disease is controlled, surgical correction of varicose veins is preferable.

• 대한한방내과학회지
• /
• 제44권5호
• /
• pp.999-1010
• /
• 2023

This case report shows the effect of Korean medicine treatment in a patient with deep vein thrombosis (DVT) after cerebral infarction who is suspected of having post-thrombotic syndrome (PTS) due to the loss of thrombus after receiving new oral anticoagulant (NOAC) treatment. The patient was treated with Korean medicine (Boyanghwano-tang and Hyulbuchuko-tang) three times a day. Acupuncture, moxibustion, infrared, and extra-physical therapy were given to the patient for 24 days. Clinical assessment - grading of edema and circumference of the left lower extremity were observed twice a week until the end of the treatment. NOAC treatment was continued for 24 days. After treatment, the patient's edema grade and circumference of the extremity improved. On the 24th day, the patient's chief complaints improved, and she requested termination of treatment. The results suggest that Korean medicine treatments, including Boyanghwano-tang, Hyulbuchuko-tang, and acupuncture therapy, can be effective in improving the clinical symptoms of DVT and PTS.

• Journal of Gastric Cancer
• /
• 제14권2호
• /
• pp.142-146
• /
• 2014

Pulmonary tumor thrombotic microangiopathy (PTTM) causing fatal pulmonary hypertension is a rare presentation of malignancy. In general, patients with PTTM rapidly succumb to death due to severe hypoxia. To date, very few cases of PTTM have been reported in the literature; and most of these cases were from gastric cancer and were diagnosed on post mortem autopsy, as it is extremely challenging to make an ante mortem diagnosis. We here report on a case of undiagnosed diffuse gastric cancer, presenting as worsening hypoxia. The clinical, radiographic, and echocardiographic features, and laboratory and pathological results were consistent with PTTM from gastric cancer. The patient was started on anticoagulation therapy, corticosteroids, and high-flow oxygen. However, her hypoxia worsened to the extent that she required ventilator support, and she died soon after intubation due to cardiac arrest. Since diffuse gastric cancer is associated with hereditary diffuse gastric cancer syndrome, cadherin 1 gene mutation analysis was performed to estimate the risk to her daughters. The test came back negative.

• Korean Circulation Journal
• /
• 제52권4호
• /
• pp.304-319
• /
• 2022

Background and Objectives: De-escalation of dual-antiplatelet therapy through dose reduction of prasugrel improved net adverse clinical events (NACEs) after acute coronary syndrome (ACS), mainly through the reduction of bleeding without an increase in ischemic outcomes. Whether the benefits of de-escalation are sustained in highly thrombotic conditions such as ST-elevation myocardial infarction (STEMI) is unknown. We aimed to assess the efficacy and safety of de-escalation therapy in patients with STEMI or non-ST-segment elevation ACS (NSTE-ACS). Methods: This is a pre-specified subgroup analysis of the HOST-REDUCE-POLYTECH-ACS trial. ACS patients were randomized to prasugrel de-escalation (5 mg daily) or conventional dose (10 mg daily) at 1-month post-percutaneous coronary intervention. The primary endpoint was a NACE, defined as a composite of all-cause death, non-fatal myocardial infarction, stent thrombosis, clinically driven revascularization, stroke, and bleeding events of grade ≥2 Bleeding Academic Research Consortium (BARC) criteria at 1 year. Results: Among 2,338 patients included in the randomization, 326 patients were diagnosed with STEMI. In patients with NSTE-ACS, the risk of the primary endpoint was significantly reduced with de-escalation (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.48-0.89; p=0.006 for de-escalation vs. conventional), mainly driven by a reduced bleeding. However, in those with STEMI, there was no difference in the occurrence of the primary outcome (HR, 1.04; 95% CI, 0.48-2.26; p=0.915; p for interaction=0.271). Conclusions: Prasugrel dose de-escalation reduced the rate of NACE and bleeding, without increasing the rate of ischemic events in NSTE-ACS patients but not in STEMI patients.

• Journal of Chest Surgery
• /
• 제43권3호
• /
• pp.266-272
• /
• 2010

배경: 심부정맥 혈전증은 폐색전증이나 만성 심부정맥 부전증을 일으킬 수 있는 질환으로 기본적인 치료로 항응고요법이 사용되어 왔다. 그러나 고식적인 항응고요법은 치료 이후 재발과 혈전후 증후군의 빈도가 높은 것으로 드러나 최근에는 중재적 시술을 이용한 치료가 적극적으로 이루어지고 있다. 이에 저자들은 하지 심부정맥 혈전증을 가진 환자들을 대상으로 중재적 치료의 유용성을 조사하였다. 대상 및 방법: 2006년 12월부터 2008년 7월까지 심부정맥 혈전증으로 중재적 시술을 시행한 29명의 환자를 대상으로 임상양상 및 치료 방법, 치료 경과를 후향적으로 조사하고 이전에 항응고제만으로 치료한 45명의 환자들을 대조군으로 하여 결과를 비교 하였다. 결과: 환자의 평균연령은 중재적 치료의 경우 55.4세, 대조군의 경우 53.7세로 두 군 모두 여자에서 더 많이 발생하였다. 도관을 이용한 혈전 용해제를 투여한 환자는 총 22명(78.5%)이었고 흡입 혈전제거술을 시행한 환자가 18명(62.0%), 스텐트를 삽입한 환자가 25명(86.2%)이었다. 폐색전증의 위험이 있어 하대정맥 내 필터를 삽입한 환자가 15명(51.7%)있었다. 대조군의 경우 저분자량 헤파린으로 치료한 경우가 39명(86.7%), 와파린을 사용할 수 없어 아스피린만으로 치료한 경우가 7명(15.6%), 헤파린으로 치료한 경우가 6명(17.8%) 있었다. 혈전용해제 또는 항응고제 사용 후 출혈로 인한 합병증은 발생하지 않았다. 추적 관찰 기간 동안 중재적 치료의 경우에 대조군과 비교하여 혈전증의 재발에는 유의한 차이가 없었으나 혈전후 증후군은 통계학적으로 유의하게 적게 나타났고(p-value=0.008) 사망한 경우가 없어 임상적으로 더 양호한 결과를 보였다. 결론: 중재적 치료는 고식적 항응고요법과 비교하여 안전하며 빠른 증상 호전과 낮은 합병증 발생률을 보이지만 아직까지 장기적인 유용성과 그 효과에 대한 연구는 이루어지지 않았으므로 향후 이 부분에 대한 연구가 필요할 것으로 생각된다.